Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2006; 131(20): 1167-1172
DOI: 10.1055/s-2006-941745
DOI: 10.1055/s-2006-941745
Übersicht | Review article
Diabetologie, Endokrinologie, Hypertensiologie© Georg Thieme Verlag KG Stuttgart · New York
Das metabolische Syndrom - Mythen, Mechanismen, Management
Metabolic syndrome - myths, mechanisms, managementFurther Information
Publication History
eingereicht: 27.1.2006
akzeptiert: 6.4.2006
Publication Date:
17 May 2006 (online)

Schlüsselwörter
Metabolisches Syndrom - kardiovaskuläre Risikofaktoren - Diabetes mellitus - Hypertonie - Adipositas - Hyperlipidämie
Key words
syndrome X - metabolic syndrome - cardiovascular risk factors - diabetes mellitus - hypertension - obesity - hyperlipidaemia
Literatur
- 1
Alberti K G, Zimmet P Z.
Definition, diagnosis and classification of diabetes mellitus and its complications.
Part 1: diagnosis and classification of diabetes mellitus provisional report of a
WHO consultation.
Diabet Med.
1998;
15
539-553
MissingFormLabel
- 2
Assmann G, Cullen P, Schulte H.
Simple scoring scheme for calculating the risk of acute coronary events based on the
10-year follow-up of the prospective cardiovascular Munster (PROCAM) study.
Circulation.
2002;
105
310-315
MissingFormLabel
- 3
Balkau B, Charles M A.
Comment on the provisional report from the WHO consultation. European Group for the
Study of Insulin Resistance (EGIR).
Diabet Med.
1999;
16
442-443
MissingFormLabel
- 4
Blüher M, Paschke R.
Visceral adipose tissue and metabolic syndrome.
Dtsch Med Wochenschr.
2003;
128
2319-2323
MissingFormLabel
- 5
Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trail Research Group .
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet.
2002;
359
2072-2077
MissingFormLabel
- 6
Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group .
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients
with impaired glucose tolerance: the STOP-NIDDM trial.
JAMA.
2003;
290
486-494
MissingFormLabel
- 7
Colwell J A.
Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus.
Am J Cardiovasc Drugs.
2004;
4
87-106
MissingFormLabel
- 8
DeFronzo R A, Ferrannini E.
Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension,
dyslipidemia, and atherosclerotic cardiovascular disease.
Diabetes Care.
1991;
14
173-194
MissingFormLabel
- 9
Despres J P, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study Group .
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
N Engl J Med.
2005;
353
2121-2134
MissingFormLabel
- 10
Dormandy J A, Charbonnel B, Eckland D J, Erdmann E, Massi-Benedetti M, Moules I K, Skene A M, Tan M H, Lefebvre P J, Murray G D, Standl E, Wilcox R G, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine R J, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PROactive investigators .
Secondary prevention of macrovascular events in patients with type 2 diabetes in the
PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):
a randomised controlled trial.
Lancet.
2005;
366
1279-1289
MissingFormLabel
- 11
Eckel R H, Grundy S M, Zimmet P Z.
The metabolic syndrome.
Lancet.
2005;
365
1415-1428
MissingFormLabel
- 12
Einhorn D, Reaven G M, Cobin R H, Ford E, Ganda O P, Handelsman Y, Hellman R, Jellinger P S, Kendall D, Krauss R M, Neufeld N D, Petak S M, Rodbard H W, Seibel J A, Smith D A, Wilson P W.
American College of Endocrinology position statement on the insulin resistance syndrome.
Endocr Pract.
2003;
9
237-252
MissingFormLabel
- 13
Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D’Armiento M, D’Andrea F, Giugliano D.
Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular
inflammation in the metabolic syndrome: a randomized trial.
JAMA.
2004;
92
1440-1446
MissingFormLabel
- 14
Ferrannini E, Buzzigoli G, Bonadonna R, Giorico M A, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S.
Insulin resistance in essential hypertension.
N Engl J Med.
1987;
317
350-357
MissingFormLabel
- 15
Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy R P, Haffner S M.
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin
Resistance Atherosclerosis Study (IRAS).
Circulation.
2000;
102
42-47
MissingFormLabel
- 16
Gale E AM.
The myth of the metabolic syndrome.
Diabetologia.
2005;
48
1679-1683
MissingFormLabel
- 17
Grundy S M, Cleeman J I, Daniels S R, Donato K A, Eckel R H, Franklin B A, Gordon D J, Krauss R M, Savage P J, Smith S C, Spertus J A, Costa F. American Heart Association; National Heart, Lung, and Blood Institute .
Diagnosis and management of the metabolic syndrome: an American Heart Association/National
Heart, Lung, and Blood Institute Scientific Statement.
Circulation.
2005;
112
2735-2752
MissingFormLabel
- 18
Hanefeld M, Leonhardt W.
Das metabolische Syndrom.
Dt Gesundheitswesen.
1981;
36
545-551
MissingFormLabel
- 19
Hanefeld M, Scriba P.
Metabolic syndrome.
Internist.
1996;
37
679-680
MissingFormLabel
- 20
Hanefeld M.
Postprandial hyperglycaemia: noxious effects on the vessel wall.
Int J Clin Pract.
2002;
129
45-50
MissingFormLabel
- 21
Hauner H.
Insulin resistance and the metabolic syndrome - a challenge of the new millennium.
Eur J Clin Nutr.
2002;
56
S25-29
MissingFormLabel
- 22
Ibrahim H A, Vora J P.
Hypertension in diabetes: a good opportunity to practise evidence-based medicine?
A commentary on the UKPDS. United Kingdom Prospective Diabetes Study.
J Hum Hypertens.
1999;
13
221-223
MissingFormLabel
- 23 International Diabetes Federation .Worldwide definition of the metabolic syndrome. (www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf) 2005
MissingFormLabel
- 24
Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen M R, Groop L.
Cardiovascular morbidity and mortality associated with the metabolic syndrome.
Diabetes Care.
2001;
24
683-689
MissingFormLabel
- 25
Kahn R, Buse J, Ferrannini E, Stern M. American Diabetes Association; European Association for the Study of Diabetes .
The metabolic syndrome: time for a critical appraisal: joint statement from the American
Diabetes Association and the European Association for the Study of Diabetes.
Diabetes Care.
2005;
28
2289-2304
MissingFormLabel
- 26
King H, Aubert R E, Hermann W H.
Global burden of diabetes, 1995 - 2025: prevalence, numerical estimates, and projections.
Diabetes Care.
1998;
21
1414-1431
MissingFormLabel
- 27
Klein S, Fontana L, Young V L, Coggan A R, Kilo C, Patterson B W, Mohammed B S.
Absence of an effect of liposuction on insulin action and risk factors for coronary
heart disease.
N Engl J Med.
2004;
350
2549-2557
MissingFormLabel
- 28
Kylien E.
Studien Hypertonie - Hyperglykämie - Hyperurikämiesyndrome.
Zentralblatt für Innere Medizin.
1923;
44
22-29
MissingFormLabel
- 29
Lakka H M, Laaksonen D E, Lakka T A, Niskanen L K, Kumpusalo E, Tuomilehto J, Salonen J T.
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged
men.
JAMA.
2002;
288
2709-2716
MissingFormLabel
- 30
LaMonte M J, Barlow C E, Jurca R, Kampert J B, Church T S, Blair S N.
Cardiorespiratory fitness is inversely associated with the incidence of metabolic
syndrome: a prospective study of men and women.
Circulation.
2005;
112
505-512
MissingFormLabel
- 31
Malik S, Wong N D, Franklin S S, Kamath T V, L’Italien G J, Pio J R, Williams G R.
Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular
disease, and all causes in United States adults.
Circulation.
2004;
110
1245-1250
MissingFormLabel
- 32
McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G.
Use of metabolic markers to identify overweight individuals who are insulin resistant.
Ann Intern Med.
2003;
139
802-809
MissingFormLabel
- 33
Meigs J B, D’Agostino R B, Wilson P W, Cupples L A, Nathan D M, Singer D E.
Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring
Study.
Diabetes.
1997;
46
1594-1600
MissingFormLabel
- 34
Meigs J B, Mittleman M A, Nathan D M, Tofler G H, Singer D E, Murphy-Sheehy P M, Lipinska I, D’Agostino R B, Wilson P W.
Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring
Study.
JAMA.
2000;
283
221-228
MissingFormLabel
- 35
Meigs J B.
Metabolic syndrome and risk for type 2 diabetes.
Exp Rev Endocrinol Metab.
2006;
1
57-66
MissingFormLabel
- 36
Orchard T J, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. Diabetes Prevention Program Research Group .
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome:
the Diabetes Prevention Program randomized trial.
Ann Intern Med.
2005;
142
611-619
MissingFormLabel
- 37
Pearson T A, Blair S N, Daniels S R, Eckel R H, Fair J M, Fortmann S P, Franklin B A, Goldstein L B, Greenland P, Grundy S M, Hong Y, Miller N H, Lauer R M, Okkene I S, Sacco R L, Sallis J F, Smith S C, Stone N J, Taubert K A.
AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update:
Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary
or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory
and Coordinating Committee.
Circulation.
2002;
106
388-391
MissingFormLabel
- 38
Pischon T, Girman C J, Hotamisligil G S, Rifai N, Hu F B, Rimm E B.
Plasma adiponectin levels and risk of myocardial infarction in men.
JAMA.
2004;
291
1730-1737
MissingFormLabel
- 39
Pyorala K, Pedersen T R, Kjekshus J, Faergeman O, Olsson A G, Thorgeirsson G.
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with
coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival
Study (4S).
Diabetes Care.
1997;
20
614-620
MissingFormLabel
- 40
Reaven G M.
Banting lecture 1988. Role of insulin resistance in human disease.
Diabetes.
1988;
37
1595-1607
MissingFormLabel
- 41
Reaven G M.
Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome.
Cell Metab.
2005;
1
9-14
MissingFormLabel
- 42
Rubins H B.
Triglycerides and coronary heart disease: implications of recent clinical trials.
J Cardiovasc Risk.
2000;
7
339-345
MissingFormLabel
- 43
Scheen A J.
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis
of randomised clinical trials.
Diabetes Metab.
2004;
30
487-496
MissingFormLabel
- 44
Shen B J, Todaro J F, Niaura R, McCaffery J M, Zhang J, Spiro A, Ward K D.
Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic
syndrome X.
Am J Epidemiol.
2003;
157
701-711
MissingFormLabel
- 45
Smyth S, Heron A.
Diabetes and obesity. The twin epidemics: Market Analysis.
Nat Med.
2006;
12
75-80
MissingFormLabel
- 46
Spranger J, Kroke A, Mohlig M, Bergmann M M, Ristow M, Boeing H, Pfeiffer A F.
Adiponectin and protection against type 2 diabetes mellitus.
Lancet.
2003;
361
226-228
MissingFormLabel
- 47
Staiger H, Häring H U.
Adipocytokines: fat-derived humoral mediators of metabolic homeostasis.
Exp Clin Endocrinol Diabetes.
2005;
113
67-79
MissingFormLabel
- 48
Taylor A J, Sullenberger L E, Lee H J, Lee J K, Grace K A.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol
(ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on
atherosclerosis progression in secondary prevention patients treated with statins.
Circulation.
2004;
110
3512-3517
MissingFormLabel
- 49
Thamer C, Machann J, Haap M, Stefan N, Heller E, Schnodt B, Stumvoll M, Claussen C, Fritsche A, Schick F, Haring H.
Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects.
Diabetes Care.
2004;
27
2726-2729
MissingFormLabel
- 50
The HOPE study investigators .
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes
mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention
Evaluation Study Investigators.
Lancet.
2000;
355
253-259
MissingFormLabel
- 51
Torgerson J S, Hauptman J, Boldrin M N, Sjostrom L.
Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized
study of orlistat as an adjunct to lifestyle changes for the prevention of type 2
diabetes in obese patients.
Diabetes Care.
2004;
27
155-161
MissingFormLabel
- 52
Tuomilehto J, Lindstrom J, Eriksson J G, Valle T T, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Finnish Diabetes Prevention Study Group .
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with
impaired glucose tolerance.
N Engl J Med.
2001;
344
1343-1350
MissingFormLabel
- 53
Vague J.
The degree of masculine differentiation of obesities, a factor determining predisposition
to diabetes, atherosclerosis, gout and uric calculous disease.
Am J Clin Nutr.
1956;
4
20-34
MissingFormLabel
- 54
Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O, Rossner S. RIO-Europe Study Group .
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular
risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Lancet.
2005;
365
1389-1397
MissingFormLabel
- 55
Vettor R, Serra R, Fabris R, Pagano C, Federspil G.
Effect of sibutramine on weight management and metabolic control in type 2 diabetes:
a meta-analysis of clinical studies.
Diabetes Care.
2005;
28
942-949
MissingFormLabel
- 56
Wajchenberg B L.
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome.
Endocrine Reviews.
2000;
21
697-738
MissingFormLabel
- 57
Wilson P W, D’Agostino R B, Parise H, Sullivan L, Meigs J B.
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus.
Circulation.
2005;
112
3066-3072
MissingFormLabel
Prof. Dr. med. M. Stumvoll
Universität Leipzig, Medizinische Klinik und Poliklinik III
Philipp-Rosenthal-Straße 27
04103 Leipzig
Phone: 0341/9713380
Fax: 0341/9713389
Email: michael.stumvoll@medizin.uni-leipzig.de